CL2020003257A1 - Compuestos antagonistas de pcsk9. - Google Patents
Compuestos antagonistas de pcsk9.Info
- Publication number
- CL2020003257A1 CL2020003257A1 CL2020003257A CL2020003257A CL2020003257A1 CL 2020003257 A1 CL2020003257 A1 CL 2020003257A1 CL 2020003257 A CL2020003257 A CL 2020003257A CL 2020003257 A CL2020003257 A CL 2020003257A CL 2020003257 A1 CL2020003257 A1 CL 2020003257A1
- Authority
- CL
- Chile
- Prior art keywords
- antagonist compounds
- pcsk9 antagonist
- pcsk9
- compounds
- macroclyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862687913P | 2018-06-21 | 2018-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003257A1 true CL2020003257A1 (es) | 2021-07-23 |
Family
ID=67263083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003257A CL2020003257A1 (es) | 2018-06-21 | 2020-12-16 | Compuestos antagonistas de pcsk9. |
| CL2022000027A CL2022000027A1 (es) | 2018-06-21 | 2022-01-05 | Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000027A CL2022000027A1 (es) | 2018-06-21 | 2022-01-05 | Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257). |
Country Status (38)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100558932B1 (ko) * | 2005-04-21 | 2006-03-10 | 주식회사 엠제이스마트 테크놀러지 | 다공성 세라믹 분리막 제조방법과, 이에 의해 제조되어진 다공성 세라믹 분리막 |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| US11814444B2 (en) | 2018-06-21 | 2023-11-14 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for PCSK9 inhibition |
| KR20250161677A (ko) | 2018-06-21 | 2025-11-17 | 머크 샤프 앤드 돔 엘엘씨 | Pcsk9 길항제 화합물 |
| EP3810129B1 (en) | 2018-06-21 | 2023-08-16 | Merck Sharp & Dohme LLC | Pcsk9 antagonist bicyclo-compounds |
| EP3810178A4 (en) | 2018-06-21 | 2022-05-04 | Merck Sharp & Dohme Corp. | CYCLIC POLYPEPTIDES TO INHIBIT PCSK9 |
| WO2019246405A1 (en) | 2018-06-21 | 2019-12-26 | Merck Sharp & Dohme Corp. | Cyclic polypeptides for pcsk9 inhibition |
| ES3015132T3 (en) | 2018-06-21 | 2025-04-29 | Ucb Holdings Inc | Cyclic polypeptides for pcsk9 inhibition |
| EP4021919A1 (en) | 2019-08-30 | 2022-07-06 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
| US12577259B2 (en) | 2019-12-20 | 2026-03-17 | Merck Sharp & Dohme Llc | PCSK9 antagonist compounds |
| SMT202500254T1 (it) | 2020-01-15 | 2025-09-12 | Janssen Biotech Inc | Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| US11932705B2 (en) | 2020-12-18 | 2024-03-19 | Merck Sharp & Dohme Llc | Cyclic polypeptides for PCSK9 inhibition |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| MX2024002146A (es) * | 2021-08-19 | 2024-03-08 | Merck Sharp & Dohme Llc | Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9. |
| SI4540267T1 (sl) | 2022-06-15 | 2026-07-31 | Merck Sharp & Dohme Llc | Ciklični peptidi za ujetje interlevkina-1 beta |
| JP7866141B2 (ja) * | 2022-08-17 | 2026-05-26 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｃｓｋ９阻害薬の結晶形態、組成物及び使用 |
| WO2024259310A2 (en) * | 2023-06-15 | 2024-12-19 | Merck Sharp & Dohme Llc | Passive permeable pcsk9 antagonist compounds |
| IL328311A (en) | 2023-11-14 | 2026-07-01 | Merck Sharp & Dohme Llc | Cyclic peptide for capturing Interleukin-1 Beta |
| AU2024401721A1 (en) | 2023-12-15 | 2026-07-16 | Merck Sharp & Dohme Llc | A cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders |
| WO2025242221A1 (zh) * | 2024-05-24 | 2025-11-27 | 上海翰森生物医药科技有限公司 | 新型修饰侧链、其制备方法和应用 |
| WO2025264781A1 (en) * | 2024-06-18 | 2025-12-26 | Kemira Oy J | Cationizing agents for saccharides and methods |
| WO2026019622A1 (en) * | 2024-07-15 | 2026-01-22 | Merck Sharp & Dohme Llc | Crystal forms of a cyclictetrapeptide and processes for preparing |
| WO2026019624A1 (en) * | 2024-07-15 | 2026-01-22 | Merck Sharp & Dohme Llc | Synthesis of cyclic oligopeptides |
| WO2026032253A1 (zh) * | 2024-08-06 | 2026-02-12 | 石药集团中奇制药技术（石家庄）有限公司 | 环肽类似物及其制备方法和用途 |
| WO2026034639A1 (ja) * | 2024-08-09 | 2026-02-12 | 株式会社Spin Wave | ペプチド合成用可溶性担体およびこれを用いた合成方法 |
| CN119930471A (zh) * | 2024-12-31 | 2025-05-06 | 苏州默迪夫生物科技有限公司 | Mk-a的制备方法、所用的中间体及其合成方法 |
| CN122464947A (zh) * | 2025-01-25 | 2026-07-28 | 深圳市祥根生物有限公司 | 一种环肽类pcsk9抑制剂和用途 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4393046A (en) | 1981-01-30 | 1983-07-12 | Merck & Co., Inc. | Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency |
| US4656269A (en) | 1986-04-15 | 1987-04-07 | Kissei Pharmaceutical Co., Ltd. | Histidine derivatives |
| DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| CZ297264B6 (cs) | 1998-09-09 | 2006-10-11 | Metabasis Therapeutics, Inc. | Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy |
| CA2415742A1 (en) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| US6852738B2 (en) | 2001-01-30 | 2005-02-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| WO2004019869A2 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| CA2495943C (en) | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| CA2512879A1 (en) | 2003-01-17 | 2004-08-12 | Soumya P. Sahoo | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| CA2667894A1 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| EP2174343A1 (en) | 2007-06-28 | 2010-04-14 | Semiconductor Energy Laboratory Co, Ltd. | Manufacturing method of semiconductor device |
| US20100179173A1 (en) | 2007-06-28 | 2010-07-15 | Daniel Guay | Substituted fused pyrimidines as antagonists of gpr105 activity |
| US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
| AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| US7928189B2 (en) | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
| WO2009148605A2 (en) | 2008-06-04 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| US20120219558A1 (en) | 2009-09-25 | 2012-08-30 | Yan Ni | Antagonists of pcsk9 |
| CA2813049A1 (en) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| NZ612544A (en) | 2010-12-28 | 2015-04-24 | Cadila Healthcare Ltd | Heterocyclic compounds suitable for the treatment of dyslipidemia |
| MX2013009258A (es) * | 2011-02-11 | 2013-10-17 | Novartis Ag | Antagonistas de pcsk9. |
| WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
| WO2012168491A1 (en) * | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| KR20140041747A (ko) | 2011-06-20 | 2014-04-04 | 제넨테크, 인크. | Pcsk9-결합 폴리펩티드 및 사용 방법 |
| MX354705B (es) | 2011-09-23 | 2018-03-16 | Novo Nordisk As | Analogos de glucagon novedosos. |
| US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
| EP2814501A4 (en) | 2012-03-13 | 2016-03-02 | Tensive Controls Inc | MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF |
| US9238676B2 (en) | 2012-05-17 | 2016-01-19 | Ra Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
| EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
| WO2014140210A1 (en) | 2013-03-14 | 2014-09-18 | Pieris Ag | Novel binding proteins for pcsk9 |
| JP2016512825A (ja) | 2013-03-15 | 2016-05-09 | シファ・バイオメディカル・コーポレイションＳｈｉｆａ Ｂｉｏｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ | 抗プロタンパク質転換酵素サブチリシン／ケキシン９型（抗ｐｃｓｋ９）化合物および心血管疾患の治療および／または予防におけるその使用方法 |
| MX373298B (es) | 2013-10-11 | 2020-05-20 | Sanofi Biotechnology | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. |
| BR122021025449B1 (pt) | 2014-06-12 | 2024-02-15 | Ra Pharmaceuticals, Inc | Composto, polipeptídeo e composição compreendendo o mesmo |
| WO2016119067A1 (en) | 2015-01-30 | 2016-08-04 | Pronasci Inc. | Peptides derived from human pcsk9 catalytic domain and uses there of for promoting ldl-r activity |
| RU2747877C2 (ru) | 2016-01-13 | 2021-05-17 | Ново Нордиск А/С | Аналоги эфр(а) с заместителями - жирными кислотами |
| CN107286158A (zh) | 2016-03-30 | 2017-10-24 | 中国科学院上海药物研究所 | 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用 |
| EP3442991A4 (en) | 2016-04-15 | 2019-11-20 | RA Pharmaceuticals, Inc. | RAS-BINDING PEPTIDES AND METHODS OF USE |
| AU2017281332A1 (en) | 2016-06-24 | 2018-12-20 | F. Hoffmann-La Roche Ag | Compositions and methods for treating cardiovascular disease |
| US10577357B2 (en) | 2016-09-19 | 2020-03-03 | The Texas A&M University System | Inhibitors of LDLR-PCSK9 protein-protein interaction and methods of their use |
| CN109284823B (zh) | 2017-04-20 | 2020-08-04 | 上海寒武纪信息科技有限公司 | 一种运算装置及相关产品 |
| CN107158002B (zh) * | 2017-07-01 | 2020-06-16 | 维亚生物科技(上海)有限公司 | 苄撑巴比妥类化合物在作为pcsk9拮抗剂和降低低密度脂蛋白中的应用 |
| WO2019246405A1 (en) | 2018-06-21 | 2019-12-26 | Merck Sharp & Dohme Corp. | Cyclic polypeptides for pcsk9 inhibition |
| ES3015132T3 (en) | 2018-06-21 | 2025-04-29 | Ucb Holdings Inc | Cyclic polypeptides for pcsk9 inhibition |
| KR20250161677A (ko) | 2018-06-21 | 2025-11-17 | 머크 샤프 앤드 돔 엘엘씨 | Pcsk9 길항제 화합물 |
| US11814444B2 (en) | 2018-06-21 | 2023-11-14 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for PCSK9 inhibition |
| EP3810178A4 (en) | 2018-06-21 | 2022-05-04 | Merck Sharp & Dohme Corp. | CYCLIC POLYPEPTIDES TO INHIBIT PCSK9 |
| EP3810129B1 (en) | 2018-06-21 | 2023-08-16 | Merck Sharp & Dohme LLC | Pcsk9 antagonist bicyclo-compounds |
| EP4021919A1 (en) | 2019-08-30 | 2022-07-06 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
| US12577259B2 (en) | 2019-12-20 | 2026-03-17 | Merck Sharp & Dohme Llc | PCSK9 antagonist compounds |
-
2019
- 2019-06-20 KR KR1020257037305A patent/KR20250161677A/ko active Pending
- 2019-06-20 IL IL279363A patent/IL279363B2/en unknown
- 2019-06-20 MD MDE20210407T patent/MD3810626T2/ro unknown
- 2019-06-20 SG SG11202012451WA patent/SG11202012451WA/en unknown
- 2019-06-20 GE GEAP201915540A patent/GEP20237506B/en unknown
- 2019-06-20 RS RS20251040A patent/RS67338B1/sr unknown
- 2019-06-20 FI FIEP19739801.9T patent/FI3810626T3/fi active
- 2019-06-20 UA UAA202100205A patent/UA129467C2/uk unknown
- 2019-06-20 JP JP2020570427A patent/JP7112531B2/ja active Active
- 2019-06-20 PL PL19739801.9T patent/PL3810626T3/pl unknown
- 2019-06-20 MA MA52967A patent/MA52967B1/fr unknown
- 2019-06-20 CN CN201980041438.5A patent/CN112313243B/zh active Active
- 2019-06-20 CA CA3102629A patent/CA3102629A1/en active Pending
- 2019-06-20 BR BR112020025274A patent/BR112020025274A8/pt unknown
- 2019-06-20 WO PCT/US2019/038155 patent/WO2019246349A1/en not_active Ceased
- 2019-06-20 EA EA202190086A patent/EA202190086A1/ru unknown
- 2019-06-20 KR KR1020217001723A patent/KR102884527B1/ko active Active
- 2019-06-20 TW TW108121413A patent/TWI840376B/zh active
- 2019-06-20 AU AU2019290163A patent/AU2019290163C1/en active Active
- 2019-06-20 HR HRP20251302TT patent/HRP20251302T1/hr unknown
- 2019-06-20 US US16/446,940 patent/US11427616B2/en active Active
- 2019-06-20 MX MX2020013726A patent/MX2020013726A/es unknown
- 2019-06-20 JO JOP/2019/0150A patent/JOP20190150A1/ar unknown
- 2019-06-20 PE PE2020002109A patent/PE20211584A1/es unknown
- 2019-06-20 IL IL321719A patent/IL321719A/en unknown
- 2019-06-20 EP EP25190624.4A patent/EP4660303A3/en active Pending
- 2019-06-20 DK DK19739801.9T patent/DK3810626T3/da active
- 2019-06-20 CN CN202511151118.9A patent/CN121130044A/zh active Pending
- 2019-06-20 PT PT197398019T patent/PT3810626T/pt unknown
- 2019-06-20 CR CR20210031A patent/CR20210031A/es unknown
- 2019-06-20 SI SI201930951T patent/SI3810626T1/sl unknown
- 2019-06-20 ES ES19739801T patent/ES3047399T3/es active Active
- 2019-06-20 LT LTEPPCT/US2019/038155T patent/LT3810626T/lt unknown
- 2019-06-20 EP EP19739801.9A patent/EP3810626B1/en active Active
- 2019-06-20 GE GEAP202215540A patent/GEAP202215540A/en unknown
- 2019-06-20 HU HUE19739801A patent/HUE073367T2/hu unknown
- 2019-06-21 AR ARP190101718A patent/AR115597A1/es unknown
-
2020
- 2020-12-14 NI NI202000101A patent/NI202000101A/es unknown
- 2020-12-16 PH PH12020552187A patent/PH12020552187A1/en unknown
- 2020-12-16 CL CL2020003257A patent/CL2020003257A1/es unknown
- 2020-12-17 DO DO2020000250A patent/DOP2020000250A/es unknown
-
2021
- 2021-01-18 EC ECSENADI20213643A patent/ECSP21003643A/es unknown
- 2021-01-19 CO CONC2021/0000456A patent/CO2021000456A2/es unknown
-
2022
- 2022-01-05 CL CL2022000027A patent/CL2022000027A1/es unknown
- 2022-06-30 US US17/854,379 patent/US12209145B2/en active Active
- 2022-07-22 JP JP2022117123A patent/JP7607615B2/ja active Active
- 2022-10-25 AU AU2022259744A patent/AU2022259744B2/en active Active
-
2024
- 2024-12-16 US US18/982,279 patent/US20250206781A1/en active Pending
- 2024-12-17 JP JP2024220762A patent/JP7855670B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000027A1 (es) | Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257). | |
| ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
| CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
| UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX2019003780A (es) | Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres. | |
| MX2017001512A (es) | Compuestos activos hacia bromodominios. | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CL2007002166A1 (es) | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. | |
| MX2020013320A (es) | Inhibidores de ectonucleotidasa y métodos de uso de los mismos. | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| MX418110B (es) | Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas | |
| CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
| EP3770148C0 (en) | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING IT AND ITS USE | |
| BR112022012205A2 (pt) | Compostos ativos para receptores nucleares | |
| CR20210021A (es) | Apirasas solubilizadas, métodos y usos | |
| BR112018006206A2 (pt) | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa | |
| MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| CL2022000895A1 (es) | Moduladores atf6 y sus usos. | |
| EP3795166A4 (en) | PHARMACEUTICAL COMPOSITION OF KOR RECEPTOR AGONIST | |
| EA202090424A1 (ru) | Бициклические ингибиторы гистондеацетилазы | |
| CL2022001393A1 (es) | Composición para la preparación de alulosa y procedimiento para la preparación de alulosa mediante el |